Axovant (AXGT) to Offer Common Stock

Axovant Gene Therapies Ltd. (Nasdaq: AXGT) announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate number of common shares plus the common shares underlying the pre-funded warrants in the offering on the same terms and conditions. All of the common shares and pre-funded warrants are being offered by Axovant.

SVB Leerink is acting as sole book-running manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

You May Also Be Interested In

• Osprey Acquisition Corp. III raises $300M in Nasdaq IPO
• Alpex Acquisition raises $115M in Nasdaq IPO led by D. Boral Capital
• Veru sets up $21.8M at-the-market stock offering